MassDevice Q&A: Amar Sawhney

Amar Sawhney has a knack for turning gel into gold.

Over the years, the serial entrepreneur managed to leverage his work in hydrogel technology at the University of Texas into the basis for six companies, including one snapped up by Genzyme early in the decade and another that Covidien predecessor Tyco Healthcare acquired in 2006.

Now the 42-year-old is looking to take a new venture, I-Therapeutix, to the next level. It’s also using hydrogels — water-based biodegradable liquids that morph into solids in the body — to develop the I-Zip ocular bandage for healing incisions in the eye after surgery. The bandage is applied as a liquid, but changes into a soft, protective barrier which then breaks down into tears when the therapy is complete.

MassDevice caught up with Sawhney this week to discuss his background, how he made the transition from inventor to CEO and his take on the regulatory and economic landscapes for the medical device industry.

MassDevice: What was your first job?

Amar Sawhney: It was a startup called Focal Inc. I started based on my graduate work in 1992 at the University of Texas. I never really had a job, so I had to build my own. I was the technology founder, not the CEO. Focal went public in 1997 and was sold to Genzyme [in 2001], but I had left by then. I was involved in the IPO but not in the sale; by then I had gone on to start Confluent Surgical.

MassDevice: So your first job was a company you started? How’d you know how to run a company?

{IMAGELEFT:http://www.massdevice.com/sites/default/wp-content/uploads/headshots/Khosravi_Fred_100x100.jpg}AS: I started out as a technical guy and of necessity I have become a chief executive. You have to know the business side to start a company. Luckily, I have my friend Fred Khosavri, who is a serial entrepreneur on the West Coast who has served as a mentor for me. We collaborate on all our ventures now.

But starting Focal was a great experience for me. I had to get a job, so I had to start my own company. When things look like they’re unfortunate, it can also be the best thing that ever happened to you. A lot of my colleagues found good careers, but I have been lucky enough to do this.

MassDevice: What’s the biggest takeaway from doing business during this recession?

AS: You have to stay true to fundamentals: Being capital-efficient, being innovative and executing rapidly. If you are true to the fundamentals, capital will always be available and you will not be leveraging any bubble.

Don’t ride waves, because sometime they’re up but they always go down. Too many people get fascinated by the bubbles. When we started Confluent, it was during the Internet bubble. Everybody was running after the latest Internet play, but we were building a successful medtech company with good products.

I don’t raise money because of of my track record. I do it only on an as-needed basis. That’s why we get appropriate valuations. If you don’t become part of these extreme events, than you won’t get dragged down when the extreme events fail.

MassDevice: What long-term effects will the recession have on your business? Will those stick, or can you wait out the storm and go back to business as usual?

AS: We build companies not only to get acquired, but to build businesses that make money in the long term. They’re not just a flash in the pan.

So when questions get asked about healthcare reform and these flash-in-the-pan events, I say, “If you have solid products helping patients improve the quality of life, improve health and reduce mortality, then those products will never go out of fashion.”

Unfortunately, the world tends to ride waves and that can be very seductive. Yes, innovation comes from waves, but sometimes they get over-capitalized and that creates wasteful habits.

A good example is some of the biotech companies that are stumbling around in need of more funding — it creates a “downer” environment. So in this environment lots of good ideas will not get funded, because of mistakes made by irrational levels of funding people did in the heyday.

MassDevice: What advice do you have for people with great ideas who can’t get funding?

AS: They can take comfort in the fact that you can continue to incubate in an academic setting, or wait until the storm passes. It’s always good to launch, but you also have to balance that with waiting for a good environment because entry is fragile. A lot of this is confidence; the actual crisis will take time to flush out of the system, but confidence will go up soon.

MassDevice: We’re in a period of great flux in the medical industry. What do you think it will look like in 20 years?

AS: There are things that have gotten out of control and now the reaction is swinging back on the community. A lot of orthopedic and spine companies were resorting to questionable practices; consequently, the onus is on the healthcare reform effort, which is putting a big burden on companies to comply with new rulings. [The gift ban] is a huge burden on companies. It will make it difficult for Massachusetts companies, because everyone is penalized for the action of a few unscrupulous players.

These new rules are changing the way we do things. Innovation will not go out of fashion, but in an environment where we can’t pay for these new innovations it’s going to be difficult to push forward. There will be changes in the healthcare system, probably where the government provides a base minimum for care. We see that in optometry with procedures like Lasik, where people pay out of pocket for it. I think there will be two poles of healthcare that may evolve towards the government paying base level and if you want premium you’ll pay out-of-pocket.

Innovation will still be there, but how you pay for it will have to change. The biggest barrier to getting markets innovated is not technology, it’s not regulation; it’s reimbursement and getting it paid for.

If you make the greatest device in the world but nobody can pay for it, what are you going to do?

There will always be people pushing the boundary, but how they will get paid will affect what devices are available. There’s no limit to human ingenuity, but it has to have a framework and checks and balances.

MassDevice: How have regulatory rule changes affected training a salesforce?

{IMAGELEFT:http://www.massdevice.com/sites/default/wp-content/uploads/headshots/Sawhney_Amar_100x100.jpg}AS: As we get into selling our products, the code of ethics needs to be robustly explained. You can’t do what orthopedic and spine companies have done. You can explain the product, but you cannot pay them to use the product. There have to be clear boundaries. The products have to stand on their own. But the level of enforcement is making it very difficult.

It’s going to be problematic, but we are still planning to be in compliance. The companies with products already in play will have a tougher time with compliance than a company like ours, which is just starting commercialization. Those companies will spend more energy doing this stuff.

It’s like Sarbanes-Oxley in that way for small companies. Sarbanes-Oxley made it very difficult to access to public markets. There is no doubt that something needs to be done, but when pendulum swings it tends to swing to the extreme.

MassDevice: When you’re building a team today, what are your focus areas — R&D, regulatory, sales and marketing, operations?

AS: It varies. When you’re getting started, you need to make sure you have a good R&D, but at the same time you need good operations people. Companies that don’t have that have a very high level of difficulty. It’s like Organogenesis, which made a great product, but they made it at a price that was higher than they could sell it at. So you have to have good operations. We do cost-of-goods analysis at a very early stage to make sure the product can be profitable. You also need good marketing, because you have to get feedback from your customers.

MassDevice: What rules or regulations have you the most concerned?

AS: Sarbanes-Oxley is always out there, because there are only three ways to get to some kind of sustainability. One of them is to sell it, two is to take it public, or three is to build a sustainable, profitable company. Sarbanes-Oxley makes it very difficult to take your company public.

MassDevice: Will the industry ever go from the face-to-face transactions gift bans make so difficult to something that can be done online?

AS: No, not really. These are procedure-specific products. It’s not pills. For years pharma wanted pills and injections that could be done the same way, without training the physicians. But medical devices need training and hand-holding and often the design is improved with physician feedback, so that loop is much more critical for medical device companies. Pharma needs the link with academia and the laboratories; medical devices need the link with physicians.

RSS From Medical Design & Outsourcing

  • Saelig presents new Amplicon Impact-R 1100F series computer
    Saelig Company announces the Amplicon Impact-R 1100F series, a fanless system powered by the Intel ATOM D2550 processor. Configured with a high performance 2.5 in. MLC Solid State Drive (SSD), the Impact-R 1100F series is a silent controller system. With options for multiple serial communication ports, the Impact-R 1100F can offer up seven DB9 connections […]
  • Gerresheimer to acquire Centor
    Gerresheimer AG, a partner to the global pharmacy and healthcare industry, will further extend its pharmaceutical packaging business with the acquisition of Centor. Gerresheimer has reached an agreement with Nemera Development S.A. to acquire 100% of the share capital of Centor US Holding. “Centor is the highly profitable market leader for plastic vials and closures in […]
  • Methods Machine Tools presents the new Nakamura-Tome NTRX-300
    Methods Machine Tools, a developer of precision machine tools and automation, has introduced the new Nakamura-Tome NTRX-300, a multitasking turning center featuring complete parts machining in one operation, with a built-in load and unload automation system and advanced operator recognition management software. The NTRX-300 features true opposing twin spindles: an 8 in. A2-6 25 HP or […]
  • MSC Apex Diamond Python and Smart Midsurface speeds modeling to validation
    MSC Software announced a new release of MSC Apex, the company’s award-winning next generation Computer Aided Engineering (CAE) platform. The MSC Apex Diamond Python release introduces: · The fourth release of MSC Apex Modeler is a CAE Specific direct modeling and meshing solution that streamlines CAD clean-up, simplification and meshing workflow. New in this release is […]
  • Quality Metrics: FDA’s plan for a key set of measurements to help ensure manufacturers are producing quality medications
    Editor’s Note: This article is written by Ashley Boam and Mary Malarkey from the “FDA Voice” blog. Boam is an FDA’s acting Director of the Office of Policy for Pharmaceutical Quality, the Office of Pharmaceutical Quality and the Center for Drug Evaluation and Research. Malarkey is an FDA’s Director if the Office of Compliance and Biologics Quality […]
  • MasterControl’s CEO talks EQMS software and new partnerships
    MasterControl offers a quality and compliance software that helps device companies speed time to market and improve their bottom lines. Under Jon’s leadership, the company has blossomed into a market leader and has a unique corporate culture that fosters growth, excellence and quality. In this podcast, MasterControl’s CEO, Jon Beckstrand, will discuss electronic quality management […]
  • BIT Group launches white label IVD solutions
    BIT Group has launched a product line of customizable IVD white label instruments. During recent years, BIT has invested capital and resources developing customizable, ready-to-use IVD systems to address a growing demand. “The IVD market is challenging for our clients,” said Marius Balger, CEO at BIT. “OEM’s must adhere to a growing number of evolving IVD […]
  • Toshiba expands line-up of ARM Cortex-M-based microcontrollers
    Toshiba announced that it has enhanced its current “TX Family” of ARM core-based microcontrollers and started to develop three series of microcontrollers, “TXZ0 series,” “TXZ3 series” and “TXZ4 series,” as part of the “TXZTM Family.” The TXZTM Family is a new collection of flash microcontrollers that support low-power consumption and high-speed operation for IoT and M2M […]
  • Parker Hannifin consolidates, layoffs ahead
    Parker Hannifin plans to consolidate a number of internal divisions, close 2 facilities and expand its Mexican operations, according to an internally distributed letter from Andy Ross, Parker’s engineered materials group president. The company has confirmed the letter was authentic, but has not disclosed how many employees will be affected by the new plans or […]
  • 3-phase current transducer from PEM delivers all-in-one convenience
    The new RCTrms 3-ph current transducer from Power Electronic Measurements (PEM) delivers a convenient, safe and accurate solution for measuring current in three phases. It features a thin, clip-around, flexible sensor coil and provides accurate true rms measurement with 4-20 mA or 0-5 V output, enabling simple installation with PLC’s, SCADA systems or automation equipment. […]
  • Safety alert: Recall on two IV solutions from Baxter
    Baxter International announced it is voluntarily recalling two lots of intravenous (IV) solutions to the hospital and user level due to the potential presence of particulate matter. The particulate matter in each case was determined to be an insect and was identified as a result of a customer complaint. The matter was identified prior to […]

Leave a Reply